Development and Research The journey of Retatrutide from concept to clinical application has been marked by rigorous research and collaboration among leading institutions
04, 2025 (GLOBE NEWSWIRE) -- Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
Retatrutide vs Tirzepatide: A Comparison When considering weight loss medications, comparing Retatrutide vs Tirzepatide provides valuable insights
Keep lifting Along with protein, strength training is the most effective way to hold on to lean muscle mass while shedding pounds
doi: 10.1016/S0140-6736(16)31679-8 Erratum in: Lancet